{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:54:46Z","timestamp":1767891286615,"version":"3.49.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Buprenorphine significantly reduces opioid-related overdose mortality. From 2002 to 2022, the Drug Addiction Treatment Act of 2000 (DATA 2000) required qualified practitioners to receive a waiver from the Drug Enforcement Agency to prescribe buprenorphine for treatment of opioid use disorder. During this period, waiver uptake among practitioners was modest; subsequent changes need to be examined.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether the Communities That HEAL (CTH) intervention increased the rate of practitioners with DATA 2000 waivers and buprenorphine prescribing.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prespecified secondary analysis of the HEALing Communities Study, a multisite, 2-arm, parallel, community-level, cluster randomized, open, wait-list\u2013controlled comparison clinical trial was designed to assess the effectiveness of the CTH intervention and was conducted between January 1, 2020, to December 31, 2023, in 67 communities in Kentucky, Massachusetts, New York, and Ohio, accounting for approximately 8.2 million adults. The participants in this trial were communities consisting of counties (n\u2009=\u200948) and municipalities (n\u2009=\u200919). Trial arm randomization was conducted using a covariate constrained randomization procedure stratified by state. Each state was balanced by community characteristics including urban\/rural classification, fatal opioid overdose rate, and community population. Thirty-four communities were randomized to the intervention and 33 to wait-list control arms. Data analysis was conducted between March 20 and September 29, 2023, with a focus on the comparison period from July 1, 2021, to June 30, 2022. Data analysis was re-run on June 6, 2024, using a revised set of data that was locked on May 31, 2024.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Waiver trainings and other educational trainings were offered or supported by the HEALing Communities Study research sites in each state to help build practitioner capacity.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The rate of practitioners with a DATA 2000 waiver (overall, and stratified by 30-, 100-, and 275-patient limits) per 100\u202f000 adult residents aged 18 years or older during July 1, 2021, to June 30, 2022, were compared between the intervention and wait-list control communities. The rate of buprenorphine prescribing among those waivered practitioners was also compared between the intervention and wait-list control communities. Intention-to-treat and per-protocol analyses were performed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 8\u202f211\u202f506 individuals aged 18 years or older were residents of the 67 communities studied. There was no evidence of an effect of the CTH intervention on the adjusted rate of practitioners with a DATA 2000 waiver (adjusted relative rate [ARR], 1.04; 95% CI, 0.94-1.14) or the adjusted rate of practitioners with a DATA 2000 waiver who actively prescribed buprenorphine (ARR, 1.00; 95% CI, 0.91-1.10).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, the CTH intervention was not associated with increases in the rate of practitioners with a DATA 2000 waiver or buprenorphine prescribing among those waivered practitioners. Supporting practitioners to prescribe buprenorphine remains a critical yet challenging step in the continuum of care to treat opioid use disorder.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04111939<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.0132","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T16:33:40Z","timestamp":1708619620000},"page":"e240132","source":"Crossref","is-referenced-by-count":6,"title":["Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing"],"prefix":"10.1001","volume":"7","author":[{"given":"Thomas J.","family":"Stopka","sequence":"first","affiliation":[{"name":"Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise C.","family":"Babineau","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin B.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Knott","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie M.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Villani","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Wai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University; Division on Substance Use Disorders, New York State Psychiatric Institute, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Blevins","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University; Division on Substance Use Disorders, New York State Psychiatric Institute, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"David","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University; Division on Substance Use Disorders, New York State Psychiatric Institute, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn A.","family":"Goddard-Eckrich","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University; Division on Substance Use Disorders, New York State Psychiatric Institute, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky Center on Drug and Alcohol Research, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Massatti","sequence":"additional","affiliation":[{"name":"Ohio Department of Mental Health and Addiction Services, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolene","family":"DeFiore-Hyrmer","sequence":"additional","affiliation":[{"name":"State of Ohio Board of Pharmacy, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Lyons","sequence":"additional","affiliation":[{"name":"College of Medicine, Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura C.","family":"Fanucchi","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky Center on Drug and Alcohol Research, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Harris","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Kentucky, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery","family":"Talbert","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Kentucky, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Hammerslag","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky Center on Drug and Alcohol Research, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Oller","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky Center on Drug and Alcohol Research, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond R.","family":"Balise","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Feaster","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Soares","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School\u2013Baystate, Springfield, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Zarkin","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LaShawn","family":"Glasgow","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Oga","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"D\u2019Costa","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouba","family":"Chahine","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Gomori","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Netrali","family":"Dalvi","sequence":"additional","affiliation":[{"name":"Office of Prescription Monitoring and Drug Control, Massachusetts Department of Public Health, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikhar","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Garner","sequence":"additional","affiliation":[{"name":"State of Ohio Board of Pharmacy, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Shadwick","sequence":"additional","affiliation":[{"name":"RecoveryOhio, Office of Ohio Governor Mike DeWine, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Salsberry","sequence":"additional","affiliation":[{"name":"Health Behavior and Health Promotion, Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Freisthler","sequence":"additional","affiliation":[{"name":"College of Medicine, Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Winhusen","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabila","family":"El-Bassel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University; Division on Substance Use Disorders, New York State Psychiatric Institute, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center, Boston, Massachusetts"},{"name":"Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kentucky Center on Drug and Alcohol Research, Lexington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"issue":"19","key":"zoi240015r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6619a1","article-title":"Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas\u2014United States.","volume":"66","author":"Mack","year":"2017","journal-title":"MMWR Surveill Summ"},{"issue":"1","key":"zoi240015r2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13722-022-00322-5","article-title":"The Rural Opioid Initiative Consortium description: providing evidence to understand the fourth wave of the opioid crisis.","volume":"17","author":"Jenkins","year":"2022","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"zoi240015r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.23631","article-title":"Geographic trends in opioid overdoses in the US From 1999 to 2020.","volume":"5","author":"Post","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi240015r5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2105\/AJPH.2021.306431","article-title":"Disparities in opioid overdose death trends by race\/ethnicity, 2018-2019, from the HEALing Communities study.","volume":"111","author":"Larochelle","year":"2021","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi240015r6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"zoi240015r7","article-title":"Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-2017.","author":"Lim","journal-title":"Addiction"},{"issue":"7","key":"zoi240015r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada.","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi240015r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi240015r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021.","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi240015r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107296","article-title":"A bifurcated opioid treatment system and widening insidious disparities.","volume":"130","author":"Guerrero","year":"2022","journal-title":"Addict Behav"},{"issue":"19","key":"zoi240015r15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder.","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240015r16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amepre.2022.05.006","article-title":"Racial\u2013Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid.","volume":"63","author":"Dunphy","year":"2022","journal-title":"Am J Prev Med"},{"key":"zoi240015r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100164","article-title":"State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements.","volume":"7","author":"Silwal","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"issue":"9","key":"zoi240015r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059328","article-title":"Protocol for community-driven selection of strategies to implement evidence-based practices to reduce opioid overdoses in the HEALing Communities Study: a trial to evaluate a community-engaged intervention in Kentucky, Massachusetts, New York and Ohio.","volume":"12","author":"Young","year":"2022","journal-title":"BMJ Open"},{"key":"zoi240015r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108329","article-title":"Addressing opioid overdose deaths: the vision for the HEALing Communities Study.","volume":"217","author":"Chandler","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108327","article-title":"Introduction to the special issue on the HEALing Communities Study.","volume":"217","author":"El-Bassel","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108335","article-title":"The HEALing (Helping to End Addiction Long-term) Communities Study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices.","volume":"217","author":"Consortium","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108325","article-title":"The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): evidence-based practices in the HEALing Communities Study.","volume":"217","author":"Winhusen","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108326","article-title":"Community engagement to implement evidence-based practices in the HEALing Communities Study.","volume":"217","author":"Sprague Martinez","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108338","article-title":"Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing Communities Study.","volume":"217","author":"Lefebvre","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108331","article-title":"Community dashboards to support data-informed decision-making in the HEALing communities study.","volume":"217","author":"Wu","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240015r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109804","article-title":"Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term) Communities Study.","volume":"245","author":"Chandler","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi240015r29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1191\/1740774504cn024oa","article-title":"Covariate-based constrained randomization of group-randomized trials.","volume":"1","author":"Moulton","year":"2004","journal-title":"Clin Trials"},{"key":"zoi240015r30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1745-6215-13-120","article-title":"Allocation techniques for balance at baseline in cluster randomized trials: a methodological review.","volume":"13","author":"Ivers","year":"2012","journal-title":"Trials"},{"issue":"CS1","key":"zoi240015r31","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v077.c01","article-title":"A SAS macro for covariate-constrained randomization of general cluster-randomized and unstratified designs.","volume":"77","author":"Greene","year":"2017","journal-title":"J Stat Softw"},{"key":"zoi240015r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108328","article-title":"Operationalizing and selecting outcome measures for the HEALing Communities Study.","volume":"217","author":"Slavova","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi240015r35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/17407745211063479","article-title":"Marginal modeling in community randomized trials with rare events: utilization of the negative binomial regression model.","volume":"19","author":"Westgate","year":"2022","journal-title":"Clin Trials"},{"issue":"3","key":"zoi240015r36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/bimj.v59.3","article-title":"Improved standard error estimator for maintaining the validity of inference in cluster randomized trials with a small number of clusters.","volume":"59","author":"Ford","year":"2017","journal-title":"Biom J"},{"issue":"1","key":"zoi240015r37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"20","key":"zoi240015r38","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1001\/jama.2023.5038","article-title":"Changes in waivered clinicians prescribing buprenorphine and prescription volume by patient limit.","volume":"329","author":"Luo","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"zoi240015r39","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.healthplace.2009.06.002","article-title":"An enhanced two-step floating catchment area (E2SFCA) method for measuring spatial accessibility to primary care physicians.","volume":"15","author":"Luo","year":"2009","journal-title":"Health Place"},{"issue":"5","key":"zoi240015r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12425","article-title":"Beyond the waiver: multilevel interventions needed to expand buprenorphine treatment.","volume":"5","author":"Samuels","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi240015r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.5996","article-title":"Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements.","volume":"5","author":"Spetz","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi240015r42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 Waiver.","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi240015r43","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/10826084.2022.2112226","article-title":"Barriers and facilitators to DATA waivered providers prescribing buprenorphine: a qualitative analysis applying the theory of planned behavior.","volume":"57","author":"Bapat","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"4","key":"zoi240015r44","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jamainternmed.2020.7497","article-title":"Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic.","volume":"181","author":"Nguyen","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10","key":"zoi240015r45","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic.","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"zoi240015r46","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.","volume":"23","author":"Walley","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"15","key":"zoi240015r47","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMp2210121","article-title":"Transforming management of opioid use disorder with universal treatment.","volume":"387","author":"Gupta","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi240015r49","doi-asserted-by":"publisher","DOI":"10.2196\/37081","article-title":"Opioid use disorder education for students and the future of opioid overdose treatment.","volume":"8","author":"Balapal","year":"2022","journal-title":"JMIR Med Educ"},{"key":"zoi240015r50","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s11606-020-06266-3","article-title":"Expanding access to medications for opioid use disorder: program and policy approaches from outside the Veterans Health Administration.","volume":"35","author":"Priest","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi240015r51","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/08897077.2021.1975867","article-title":"A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.","volume":"43","author":"Taylor","year":"2022","journal-title":"Subst Abus"},{"issue":"4","key":"zoi240015r52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1377\/hlthaff.2020.01251","article-title":"Medicaid expansion increased medications for opioid use disorder among adults referred by criminal justice agencies.","volume":"40","author":"Khatri","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi240015r53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","article-title":"Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.","volume":"5","author":"Kraus","year":"2011","journal-title":"J Addict Med"},{"key":"zoi240015r9","volume-title":"Medications for Opioid Use Disorder Save Lives","year":"2019"},{"key":"zoi240015r4","unstructured":"Centers for Disease Control and Prevention. Provisional data shows US drug overdose deaths top 100,000 in 2022. May 28, 2023. Accessed July 1, 2023. https:\/\/blogs.cdc.gov\/nchs\/2023\/05\/18\/7365\/"},{"key":"zoi240015r10","unstructured":"SAMHSA. Statutes, regulations, and guidelines: medication assisted treatment. Accessed November 22, 2022. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines"},{"key":"zoi240015r11","unstructured":"SAMHSA. Become a buprenorphine waivered practitioner. Accessed November 15, 2022. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/become-buprenorphine-waivered-practitioner"},{"key":"zoi240015r18","unstructured":"Bloomberg Law. Five areas likely to force HHS action in 2023. December 28, 2022. Accessed January 3, 2023. https:\/\/news.bloomberglaw.com\/health-law-and-business\/five-areas-likely-to-force-hhs-action-in-2023"},{"key":"zoi240015r19","unstructured":"ASPE. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS buprenorphine practice guidelines. December 22, 2022. Accessed December 5, 2022. https:\/\/aspe.hhs.gov\/reports\/early-changes-after-2021-hhs-buprenorphine-practice-guidelines"},{"key":"zoi240015r33","unstructured":"National Center for Health Statistics. U.S. Census populations with bridged race categories. https:\/\/www.cdc.gov\/nchs\/nvss\/bridged_race.htm"},{"key":"zoi240015r34","unstructured":"Census Bureau. 2017\u20132021 ACS 5-year estimates. https:\/\/www.census.gov\/programs-surveys\/acs\/technical-documentation\/table-and-geography-changes\/2021\/5-year.html"},{"key":"zoi240015r48","unstructured":"Governor\u2019s Medical Education Working Group on Prescription Drug Misuse. Medical education core competencies for the prevention and management of prescription drug misuse. November 2015. Accessed December 15, 2023. https:\/\/www.mass.gov\/doc\/medical-education-core-competencies-for-the-prevention-and-management-of-prescription-drug-2\/download"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2815389\/stopka_2024_oi_240015_1724087464.96.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T17:30:27Z","timestamp":1724088627000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2815389"}},"subtitle":["A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0132","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}